Amber Therapeutics

Amber Therapeutics is a medical technology company specializing in developing and delivering breakthrough neuromodulation therapies to address areas of unmet clinical need. Founded in 2021, the company has quickly assembled a multidisciplinary team with deep medical device expertise and a commitment to transformational innovation. Amber's initial focus is on developing a novel therapy for mixed urinary incontinence (MUI), a debilitating condition that affects millions worldwide. Their flagship product, the Amber-UI, is a fully implantable system that targets the pudendal nerve with a device capable of both stimulating and sensing physiological responses, allowing for personalized and adaptive treatment.

Amber's mission is to restore normal physiological function in women suffering from MUI. The company is actively engaged in clinical research, with their AURA-2 study demonstrating the safety and feasibility of their surgical procedure and showing promising clinical efficacy and quality of life improvements. Amber Therapeutics is committed to bringing innovative and effective solutions to patients with functional disorders of the peripheral nervous system, setting a new standard for neuromodulation therapy.

Amber Therapeutics does not explicitly mention any job flexibility options on their website or in the provided job posting. Therefore, it is not possible to determine the company's stance on remote work, flexible hours, or other forms of job flexibility.

Amber Therapeutics is a medical technology company developing innovative, intelligent bioelectrical therapies to transform clinical outcomes for patients with functional disorders of the peripheral nervous system. Their first therapy, Amber-UI, is a closed-loop neuromodulation system designed to treat women suffering from mixed urinary incontinence. The company's mission is to restore normal physiological function in these patients, ultimately improving their quality of life.

Amber Therapeutics fosters a culture of innovation and collaboration, valuing a multidisciplinary team with deep medical device experience. The company embraces a mindset focused on transformational innovation, aiming to deliver breakthrough neuromodulation therapies that address unmet clinical needs. This is evident in their research efforts, which are supported by a consortium of academic collaborators, and their ambitious clinical trial portfolio. Amber's culture emphasizes the importance of teamwork, scientific rigor, and a commitment to improving patient outcomes.